Active Biotech AB - Interim report January - September 2017

(Thomson Reuters ONE) -




Third quarter in brief
* The company's application related to one of the patent families in the SILC
project was granted patent in the US
* Preclinical data for a SILC substance was published in the scientific
journal Cancer Immunology Research
* The process to divest the company's research facility at Ideon in Lund has
been initiated, for further comments related to the company's liquidity
situation see the section "Outlook, including significant risks and
uncertainties"

Events after the end of the period
* In October, Active Biotech's partner Teva Pharmaceutical Industries Ltd
presented new data concerning laquinimod for the treatment of multiple
sclerosis at the ECTRIMS-ACTRIMS congress
* The Board of directors has decided to initiate negotiations with the trade
unions related to the winding up of the companies animal test facility

Financial summary
SEK M July-Sept. Jan.-Sept. Full-year

  2017 2016 2017 2016 2016
-------------------------------------------------------------------------------


Net sales 5.1 4.1 14.8 12.0 19.0

Operating loss -6.5 -11.1 -44.2 -41.6 -55.1

Loss for the period -8.4 -12.4 -48.6 -44.8 -59.6

Loss per share, before and after dilution -0.09 -0.14 -0.50 -0.50 -0.65
(SEK)

Cash and cash equivalents (at the end of     35.6 39.9 77.7
the period)



For further information, please contact:
  Helén Tuvesson, CEO Active Biotech AB
  Tel: +46 (0)46-19 21 56 (Corp. Reg. No. 556223-9227)
  Box 724, SE-220 07 Lund

  Hans Kolam, CFO Tel: +46 (0)46-19 20 00
  Tel: +46 (0)46 19 20 44

The report is also available at www.activebiotech.com.

Active Biotech AB - Interim report January - September 2017 :
http://hugin.info/1002/R/2148297/824106.pdf



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.

Source: Active Biotech via GlobeNewswire

Weitere Infos zu dieser Pressemeldung:
Unternehmensinformation / Kurzprofil:
Bereitgestellt von Benutzer: hugin
Datum: 09.11.2017 - 08:30 Uhr
Sprache: Deutsch
News-ID 567378
Anzahl Zeichen: 2741

contact information:
Town:

LUND

Kategorie:

Business News

Diese Pressemitteilung wurde bisher 185 mal aufgerufen.


Die Pressemitteilung mit dem Titel:
"Active Biotech AB - Interim report January - September 2017"
steht unter der journalistisch-redaktionellen Verantwortung von

Active Biotech (Nachricht senden)

Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).

Primary endpoint reached in Active Biotech's TASQ Phase II clinical trial i ...

Lund, Sweden, December 14, 2009 - A first analysis of the primary endpoint based on data from at least six months' treatment of more than 200 patients, has been performed in Active Biotech AB's (NASDAQ OMX Nordic: ACTI) ongoing Phase II cli ...

Active Biotech's election committee appointed ...

In accordance with a decision made by the Annual General Meeting held on May 7, 2009, the Election Committee shall comprise the representatives for the three largest shareholders on September 30 and the Board Chairman. For the 2010 Annual General ...

Active Biotech AB Interim Report, January - September 2009 ...

* Laquinimod -- new data presented at ECTRIMS * 57-57 -- exploratory clinical trial in progress * RhuDex(TM) -- clinical development to continue following feedback from UK MHRA * ANYARA -- complete Phase I data published * TASQ -- complete Phase I ...

Alle Meldungen von Active Biotech